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ABSTRACT: Reaction of [ReOCl3(PPh3)2] or [ReO2I(PPh3)2] with 2,2
/-diphenylglycine 
(dpgH2) in refluxing ethanol afforded the air stable complex [ReO(dpgH)(dpg)(PPh3)] (1). 
Treatment of  [ReO(OEt)I2(PPh3)2] with 1,2,3-triaza-7-phosphaadamantane (PTA) afforded the 
complex [ReO(OEt)I2(PTA)2] (2). Reaction of [ReOI2(PTA)3] with dpgH2 led to the isolation 
of the complex [Re(NCPh2)I2(PTA)3]·0.5EtOH (3·0.5EtOH). A similar reaction but using 
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[ReOX2(PTA)3] (X = Cl, Br) resulted in the analogous halide complexes 
[Re(NCPh2)Cl2(PTA)3]·2EtOH (4·2EtOH) and [Re(NCPh2)(PTA)3Br2]·1.6EtOH 
(5·1.6EtOH). Using benzilic acid (2,2/-diphenylglycolic acid, benzH) with 2 afforded the 
complex [ReO(benz)2(PTA)][PTAH]·EtOH  (6·EtOH). The potential for the formation of 
complexes using radioisotopes with relatively short half-lives suitable for nuclear medicine 
applications by developing conditions for of [Re(NCPh2)(dpg)I(PTA)3]  (7)[ReO4]
- in a 4 h 
timescale. A procedure the technetium analog of complex [Re(NCPh2)I2(PTA)3] (3) from 
99mTc[TcO4]
- was then investigated.  The molecular structures of 1 – 7 are reported, whilst 3-7 
have been studied using in vitro cell assays (Hela, HCT116, HT-29 and HEK 293) and were 
found to have IC50 values in the range 29 to 1858 µM.  
INTRODUCTION  
 
The diagnosis and early treatment of diseases such as cancer and heart disease have benefited 
greatly from the availability of technetium-based imaging agents.1 99mTc is used as a -emitter 
in single photon emission computed tomography (SPECT). Moreover, 99mTc has been used for 
diagnosis as an imaging agent because of the optimal 140-keV γ-ray emission, the 6 h half-life, 
lower tissue damage and the availability of a convenient generator.2-5 By contrast, rhenium has 
two isotopes that are -emitters, namely 186Re and 188Re with half-lives (t½) of 90 and 17 h 
respectively, making them suitable as therapeutics in a theranostic pair with technetium.6 Given 
the similarities between the chemistries of these two metals, any advances in the synthetic 
methodology to access one type of metal chelate can usually be applied to the other metal and 
vice versa.2,7 Currently much research effort is devoted to developing targeted agents, thereby 
ensuring any delivered radiation is localized.3,8,9  
The use of chelates with added functional groups is a particularly promising avenue,10 and 
with this in mind, we have initiated a programme to investigate the use of amino acid derived 
chelates bound to rhenium. We note that data concerning the cellular uptake, toxicity and 
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localization of rhenium amino acid complexes is scant.11 Moreover, the use of amino acid 
derived ligation at the rhenium core has been recognized as a potential method for modulating 
toxicity, localization etc. in mammalian cells.11,12 The use of amino acids has allowed for the 
development of many new chelate families, particularly where steric bulk is not a prerequisite 
for complex formation.13,14 They can also act as bifunctional chelators i.e. can attach to targeted 
biomolecules and bear coordination sites to the radionuclide that can direct the biodistribution 
of the radiotracer.15-17 The use of simples carboxylic acids also allows for optical properties of 
metal complexes to be probed with a view to enhancing their bio-application.18,19   In other 
studies, we and others have found that the use of the acids Ph2C(X)CO2H (X = OH, NH2) can 
impart high crystallinity in products and be beneficial for characterization.20-23 Thus, herein we 
report our initial studies on rhenium complexes bearing ligands derived from diphenylglycine 
(X = NH2) and the related pro-ligand benzilic acid (X = OH).  
Convenient entry points into high oxidation state rhenium chemistry are the phosphine 
complexes [ReOCl3(PPh3)2] and [ReO2I(PPh3)2], however it must be noted that the low 
biocompatibility, high molecular weight and hydrophobicity of arylphosphines renders these 
complexes unsuitable for medical uses.24 The challenge, therefore, is to replace PPh3 with a 
more biocompatible and hydrophilic phosphine. 1,2,3-Triaza-7-phosphaadamantane (PTA) is 
a phosphine that is widely used as a water-soluble ligand, and possesses an adamantane-like 
structure. Daigle et al. first prepared this phosphine in 1974, and because of its solubility and 
stability in water, it has been widely used in the fields of organometallic catalysis and 
coordination chemistry;25,26 others have recently published on the coordination chemistry of 
PTA and outlined its medical and catalytic chemistry.27-30 Thus, herein we have employed PTA 
to produce water-soluble rhenium complexes for facile biological evaluation. We also note that 
the rhenium oxo complexes can be isolated from [3 + 2] reactions involving diphenyl ketene.31 






Scheme 1. 2,2/-Diphenylglycine (dpgH2) and benzilic acid (2,2
/-diphenylglycolic acid, benzH). 
                                                                                                    
Scheme 2. Complexes 1 to 7 prepared herein. 
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Finally, given the aim of this work is to develop new technetium-based imaging agents, we 
have conducted the preparation of a water soluble dpgH2-derived rhenium complex from 





General Information. All manipulations were carried out under an atmosphere of dry 
nitrogen using conventional Schlenk and cannula techniques or in a conventional nitrogen-
filled glove box. Hexane and ethanol were dried over sodium prior to use. Dichloromethane 
was refluxed over calcium hydride. Diethylether was dried over sodium benzophenone. All 
solvents were distilled and degassed prior to use. IR spectra (nujol mulls, KBr windows) were 
recorded on a Nicolet Avatar 360 FT IR spectrometer; 1H NMR spectra were recorded at room 
temperature on a Varian VXR 400 S spectrometer at 400 MHz or a Gemini 300 NMR 
spectrometer or a Bruker Advance DPX-300 spectrometer at 300 MHz. The 1H NMR spectra 
were calibrated against the residual proton impurity of the deuterated solvent. Elemental 
analyses were performed by the elemental analysis service at the London Metropolitan 
University and the Department of Chemistry & Biochemistry at the University of Hull.  
The precursors [ReOCl3(PPh3)2], [ReOBr3(PPh3)2], [ReO2I(PPh3)2], [ReO(OEt)I2(PPh3)2] 
and [ReOX2(PTA)3] (X = Cl; for X =  Br, I, a similar method was employed) were prepared by 
the literature methods.24,32-34  All other chemicals were purchased from Sigma Aldrich.  
Synthesis of [ReO(dpgH)(dpg)(PPh3)] (1). To [ReOCl3(PPh3)2] (0.50 g, 0.60 mmol) and 2,2
/-
diphenylglycine (0.27 g, 1.20 mmol) was added dry ethanol (20 mL). After refluxing for 4 h, 
volatiles were removed in vacuum and the residue was extracted into CH2Cl2 (20 mL). Addition 
of a layer of Et2O (20 mL) afforded, on prolonged standing, green prisms of 1. Yield: 0.40 g 
(74%). Elemental Anal. Calcd for C46H38N2O5PRe: C, 60.26%; H, 4.14%; N, 3.05%. Found: 
C, 59.93%; H, 4.00%; N 3.02%. 1Η ΝΜR (CDCl3) δ: 11.24 (s, 1H, NH), 7.13-7.51 (m, 21H, 
HaromPPh3/CPh2), 6.98 (d, J = 8.2 Hz, 6H, HaromPPh3), 6.67 (d, J = 11.4 Hz, 8H, Harom CPh2), 
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5.92 (d, J = 11.4 Hz, 2H, NH2).
31P NMR (CDCl3) δ: 5.3 (s). IR (KBr): 3303 (w), 3258 (w), 
1584 (m), 1569 (m), 1092 (s), 998 (s), 980 (s), 955 (s), 936 (s), 908 (s) cm-1. MALDI-MS: m/z: 
917.21 [M + H+].  
Synthesis of [ReO(dpgH)(dpg)(PPh3)] (1) from [ReO2I(PPh3)2]. As above, but using 
[ReO2I(PPh3)2] (0.50 g, 0.57 mmol) and 2,2
/-diphenylglycine (0.26 g, 1.14 mmol) affording 1 
as green prisms. Yield: 0.30 g (57%). Elemental Anal. Calcd for C46H38N2O5PRe: C, 60.26%; 
H, 4.14%; N, 3.05%. Found: C, 60.32%; H, 3.89%; N, 3.07%. 1Η ΝΜR (CDCl3) δ: 11.24 (s, 
1H, NH), 6.91-7.72 (m, 21H, HaromPPh3/CPh2), 6.66 (d, J = 11.5, 14H, HaromPPh3/CPh2), 5.92 
(d, J = 11.5, 2H, NH2). 
31P NMR (CDCl3) δ: 5.3 (s). IR (KBr): 3301 (w), 3256 (w), 1584 (w), 
1569 (w), 1092 (s), 998 (s), 979 (m), 955 (m), 936 (m), 908 (m) cm-1. MALDI-MS: m/z: 917.21 
[M + H+].  
Synthesis of [ReO(OEt)I2(PTA)2] (2). At room temperature, 1,3,5-triaza-7-
phosphaadamantane (0.51 g, 3.27 mmol)  was dissolved in the minimum volume of 
dichloromethane (~30 mL) and the solution is added to a conical flask containing a suspension 
of [ReO(OEt)I2(PPh3)2] (1.00 g, 1.09 mmol)  in dichloromethane (20 ml) which caused a color 
change from light khaki to yellow-orange. The reaction mixture was stirred for 1 h, and then 
the volatiles were removed under vacuum. Ethanol (5 mL) was added, and slow evaporation 
of the solvent at room temperature afforded a yellow-orange solid, which was collected, 
washed with EtOH (10 mL) and Et2O (10 mL). Orange crystals of 2 suitable for X-ray 
crystallography were obtained by recrystallization from CH2Cl2/EtOH. Yield: 0.81 g (92%). 
Elemental Anal. Calcd for C14H29I2N6O2P2Re: C, 20.60%; H, 3.55%; N, 10.30%. Found: C, 
21.01%; H, 3.95%; N, 10.64%. 1Η ΝΜR (CDCl3) δ: 4.48-4.74 (m, 2H, CH2), 4.03-4.35 (m, 
12H, N-CH2-N), 3.87 (d, J = 9.2 Hz, 12H, P-CH2), 1.58 (s, 3H, CH3). 
31P NMR (CDCl3) δ: -
4.8 (s); in (D2O) δ: -2.2 (s). IR (KBr): 1281 (m), 1040 (m), 1013 (s), 969 (s), 945 (s), 902 (s) 
cm-1. MALDI-MS: m/z: 816.95 [M + H+].  
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Synthesis of [Re(NCPh2)I2(PTA)3]·0.5EtOH  (3·0.5EtOH). To [ReOI2(PTA)3] (0.50 g, 0.53 
mmol) and dpgH2 (0.24 g, 1.07 mmol) was added dry ethanol (20 mL). After refluxing for 4 h, 
the solution was filtered and on prolonged standing (2 to 3 days) at ambient temperature green 
crystals of 3 formed. Yield: 0.40 g (68%). Elemental Anal. Calcd for 
C64H88I4N20P6Re2·0.5EtOH: C, 34.57%; H, 4.41%; N, 12.60%. Found: C, 34.90%; H, 4.79%; 
N, 12.72%. 1Η ΝΜR (C6D6) δ: 7.05-7.29 (m, 10H, HaromCPh2), 3.85-4.08 (m, 18H, N-CH2-N), 
3.66 (d,  J = 41.6 Hz, 18H, P-CH2).
31P NMR (C6D6) δ: -104.9 (t, J = 11.3 Hz), -120.9 (d, J = 
12.5 Hz); in (CDCl3) δ: -104.2 (t, J = 12.5 Hz), -118.7 (d, J = 12.5 Hz); in (D2O) δ: -107.3 (t, 
J = 11.3 Hz), -123.3 (d, J = 12.5 Hz). IR (KBr): 1592 (w), 1416 (m), 1313 (m), 1276 (s), 1241 
(s), 1041 (m), 1015 (s), 969 (s), 946 (s) cm-1. ES-MS: m/z: 1092 [M + H+].  
Synthesis of [Re(NCPh2)Cl2(PTA)3]·2EtOH  (4·2EtOH). To [ReOCl2(PTA)3] (0.50 g, 0.68 
mmol) and dpgH2 (0.27 g, 1.10 mmol) was added dry ethanol (20 mL). After refluxing for 4 h, 
the solution was filtered and on prolonged standing (2 to 3 days) at ambient temperature green 
crystals of 4 formed. Yield: 0.40 g (67%). Elemental Anal. Calcd for C31H46Cl2N10P3Re 
(sample dried in-vacuum -2EtOH): C, 40.93%; H, 5.06%; N, 15.40%. Found: C, 40.52%; H, 
4.95%; N, 15.01%. 1Η ΝΜR (C6D6) δ: 7.06-7.29 (m, 10H, HaromCPh2), 3.55-3.63 (m, 18H, N-
CH2-N), 3.19 (d, J = 8.7 Hz, 18H, P-CH2).
31P NMR (C6D6) δ:  - 82.0 (t, J = 10.0 Hz), -94.9 (d, 
J = 10.0 Hz); in (CDCl3) δ: -81.2 (t, J = 10.0 Hz), -94.2 (d, J = 10.0 Hz); in (D2O) δ: -77.4 (t, 
J = 10.0 Hz), -91.6 (d, J = 7.5 Hz). IR (KBr): 1598 (w), 1462 (s), 1315 (w), 1281 (w), 1242 
(w), 1040 (w), 1015 (m), 972 (m), 947 (m) cm-1.MALDI-MS: m/z: 909.20 [M + H+].  
Synthesis of [Re(NCPh2)Br2(PTA)3]·1.6EtOH  (5·1.6EtOH). To [ReOBr2(PTA)3] (0.50 g, 
0.60 mmol) and dpgH2 (0.27 g, 1.20 mmol) was added dry ethanol (20 mL). After refluxing 
for 4 h, the solution was filtered and on prolonged standing (2 to 3 days) at ambient temperature 
green crystals of 5 formed. Yield: 0.35 g (58%). Elemental Anal. Calcd for 
C31H46Br2N10P3Re·0.5EtOH (sample dried in-vacuum, -1.1EtOH): C, 37.64%; H, 4.80%; N, 
13.72%. Found: C, 37.83%; H, 5.18%; N, 13.26%. 1Η ΝΜR (DMSO-D6) δ: 7.53 (t,  J = 7.8 
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Hz, 6H, HaromCPh2), 6.94-7.11 (m, 4H, HaromCPh2), 3.91-4.39 (m, 18H, N-CH2-N), 3.73 (d,  J 
= 9.6 Hz, 18H, P-CH2).
31P NMR (DMSO-D6) δ: -87.5 (t, J = 10.0 Hz), -103.6 (d, J = 10.0 Hz); 
in (CDCl3) δ: -89.4 (t, J = 10.0 Hz), -103.3 (d, J = 10.0 Hz); in (D2O) δ: -70.8(m), -82.2 (d, J 
= 5 Hz). IR (KBr): 1459 (s), 1376 (s), 1281 (m), 1277 (m), 1239 (m), 1094 (s), 1040 (m), 1011 
(s), 969 (s), 945 (s) cm-1. MALDI-MS: m/z: 840.68 [M - PTA].  
Synthesis of [ReO(benz)2(PTA)][PTAH]·EtOH (6·EtOH). To [ReO(OEt)I2(PTA)2] (0.61 g, 
0.74 mmol) and benzilic acid (0.34 g, 1.48 mmol) was added dry ethanol (20 mL). After 
refluxing for 4 h, the solution was allowed to cool to room temperature, whereupon purple 
crystals of 6·EtOH formed. Yield: 0.50 g (68%). Elemental Anal. Calcd for 
C82H96N12O15P4Re2: C, 49.47%; H, 4.87%; N, 8.47%. Found: C, 49.35%; H, 4.60%; N, 8.65%. 
1Η ΝΜR (C6D6) δ: 7.24-7.96 (m, 20H, HaromCPh4), 3.22-3.29 (m, 12H, N-CH2-N), 2.91 (d, J = 
7.8 Hz, 12H, P-CH2). 
31P NMR (C6D6) δ: -90.4 (s), -94.5 (s); in (D2O) δ: -88.5 (s), -91.6 (s). 
IR (KBr): 1656 (s), 1631 (s), 1025 (s), 1011 (m), 981 (w), 969 (s), 945 (s), 923 (w) cm-1. 
MALDI-MS: m/z: 971.24 [M + H+]. 
Synthesis of [Re(NCPh2)(dpg)I(PTA)3]·2C6D6 (7·2C6D6). Ammonium perrhenate (1.09 g, 
4.10 mmol) and triphenylphosphine (5.00 g, 19.0 mmol) were stirred in ethanol (30 mL). 
Hydroiodic acid (56%, 5 mL) was then added carefully and the brown mixture was heated 
under reflux for 15 min. The obtained olive-green solid was filtered off and washed with 
ethanol (25 mL) and diethylether (25 mL), with no further drying. This compound was then 
added to the solvent mixture (1:25) (water: acetone), which was stirred in an ice bath for 30 
min. A violet compound [ReO2I(PPh3)2] precipitated which was then filtered off and dried in 
vacuum. 1,3,5-triaza-7-phosphaadamantane (2.17 g, 13.8 mmol) was dissolved in a minimum 
volume of dichloromethane, and the solution was then mixed (at room temperature) with the 
pre-prepared [ReO2I(PPh3)2] (2.00 g, 2.30 mmol) dissolved in dichloromethane (30 mL); the 
color changed from a dark to a pale brown. The reaction mixture was stirred for 40-50 min, 
following which the volume of the solution was reduced in under vacuum to remove any 
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volatiles. Ethanol (5 mL) was then added, and after 5 min., the remaining solvent was removed 
using a rotary evaporator. The obtained product was then washed with ethanol to give a yellow-
orange solid [ReO2I(PTA)3]. Finally, [ReO2I(PTA)3] (2.00 g, 2.44 mmol) and dpgH2 (1.11 g, 
4.88 mmol) were mixed in ethanol (20 mL).  The reaction was then stirred at 100°C under 
reflux for 90 min. to produce a green solution. This green solution was filtered and the solvent 
then removed via rotary evaporation to produce a fine green solid of complex 7. Yield: 1.80 g 
(62%). Green crystals suitable for X-ray analysis were obtained by recrystallization of the 
product [Re(NCPh2)(dpg)I(PTA)3] (7) in benzene. Elemental Anal. Calcd for 
C45H58I1N11P3Re: C, 45.34%; H, 4.86%; N, 12.93%. Found: C, 45.12%; H, 5.12%; N 12.72%. 
1Η ΝΜR (C6D6) δ: 7.64 (d, J = 8.3 Hz, 4H, HaromCPh2 ), 6.82-7.34 (m, 6H, HaromCPh2), 3.55-
4.34 (m, 32H, CH2(PTA)), 3.17-3.40 (m, 2 H, NH2).
31P NMR (C6D6) δ: -4.7 (s), -102.3 (s); in  
(CDCl3) δ: -4.8 (s), -98.2 (s); in (D2O) δ: - 2.2 (s), -95.3 (s). IR (KBr): 3409 (w), 1633 (m), 
1035 (w), 1012 (s), 968 (m), 945 (m) cm-1. MALDI-MS: m/z: 1191.80 [M]+, 1175.85 [M+ - 
NH2].   
Synthesis of [99mTc][Tc(NCPh2)I2(PTA)3]. [
99mTc]TcO4
- was eluted in saline from a Ultra 
Technekow™ FM 99Mo/99mTc generator (Curium, UK) and 100 µl (~200 MBq, in saline) was 
added to a 2 ml glass vial containing a mixture of 900 µl of dimethylformamide (DMF),  
triphenylphosphine (66.5 mg, 0.255 mmol) and hydroiodic acid (66.5 µl, 0.883 mmol) and 
heated at 137°C for 30 minutes. After allowing to cool, a solution of 1,3,5-triaza-7-
phosphaadmantane (3.7 mg, 0.0235 mmol) in DMF (100 µl) was added to the reaction mixture 
and stirred for 40 mins at 99°C. Finally, a solution of 2,2/-diphenylglycine (0.17 mg, 0.00074 
mmol) in DMF (10 µl) is added to the reaction mixture and stirred at 137°C for 2 hours. Quality 
control analysis is carried out by HPLC or radio-TLC. Radio-TLC were carried out on 
aluminum-backed silica TLC plates with saline as the mobile phase. Detection was performed 
using a Scan-RAM Radio TLC detector. [99mTc]TcO4
- RF = 0.967, [99mTc] [TcO2I(PPh3)2] RF 




HPLC conditions. HPLC analysis was performed on an Agilent 1100 Series system 
equipped with a diode array UV (detection at 254 nm) and LabLogic NaI crystal gamma 
detectors controlled by Laura software.  
The analytical HPLC was performed on a Gemini® 5 µm C18 110 Å LC column 150×4.6 
mm (Phenomenex) at a flow rate of 1 mL min-1, with a mobile phase consisting of methanol 
with 0.1% TFA  (solvent A) and water with 0.1% TFA  (solvent B). Gradient 1 
[time/min](solvent A: solvent B): [0-2](50:50), [2-17](95:5), [17- 22](95:5), [22-26](50:50). 
The HPLC sample was prepared by taking 10 l of sample dissolved in 90 l of methanol.  
Semi-preparative HPLC was carried out on Luna® 5 µm C18(2) 100 Å LC column 250×10 
mm (Phenomenex) and Pursuit 200Å C18 10×250 mm 10 µm HPLC column (Agilent) at a 
flow rate of 5 mL min-1, with a mobile phase consisting of methanol with 0.1% TFA  (solvent 
A) and water with 0.1% TFA  (solvent B). Semi-preparative gradient [time/min](solvent 
A:solvent B): [0-2](95:5), [2-22](95:5-50:50), [0-2](95:5), [2-22](95:5-50:50). Prior to the 
HPLC purification, the reaction mixtures were passed through C-18 cartridges to trap unreacted 
[99mTc]TcO4
-.  
X-ray Crystallography. X-ray diffraction data from single crystals of 3·0.5EtOH and 
6·EtOH were collected at the EPSRC Crystallography service in Southampton, UK. For the 
other samples, full sets of X-ray diffraction intensity data were collected in series of ω-scans 
using a Stoe IPDS2 image plate diffractometer operating with Mo K radiation at 150(2) K. A 
multi-scan method was applied for the absorption corrections of the collected data.35  
The structures were solved using dual-space methods within SHELXT and full-matrix least 
squares refinement was carried out within SHELXL-2018 via the WinGX program 
interface.36,37 All non-hydrogen positions were located in the direct and difference Fourier 
maps and refined using anisotropic displacement parameters. Crystal structure data for the 
compounds reported here are summarized in Table 1.
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Table 1.  Crystallographic data for complexes 1 - 7.  
Compound 1 2 3 4 5 6 7 
Empirical 
formula 







Formula weight 915.95 815.37 
 
2219.36 908.79 997.71 1985.98 1332.34 
Temperature 100(2)K 100(2) K 100(2) K 150(2)K 150(2) K 150(2) K 150(2) K 
Wavelength 0.71075 Å 0.71073 Å 0.71075 Å 0.71073 Å 0.71073 Å 0.71075 Å 0.71073 Å 
Crystal system Triclinic Monoclinic Triclinic Triclinic Triclinic Triclinic Monoclinic 
Space group P-1 P 21/n 
 
P -1 P -1 P -1 P -1 P 21/n 
 
Unit cell dimensions         
a [Å] 13.2798(2) 25.1208(13) 10.22760(10) 10.3595(14) 10.1478(7) 9.5325(2) 11.7130(4) 
b [Å] 23.0757(5) 6.8178(4) 13.56420(10) 11.1139(16) 13.6036(9) 10.6561(2) 17.6413(6) 
c [Å] 26.1765(6) 26.2202(15) 15.3839(2) 18.707(4) 15.4971(10) 20.9031(4) 27.1727(8) 
α [°] 108.600 (2) 90 84.3800(10) 100.944(14) 83.257(5) 78.781(2) 90 
β [°] 92.629(2) 99.070(4) 81.5650(10) 98.250(13) 80.541(5) 87.0180(10) 91.979(3) 
γ [°] 91.153(2) 90 79.7640(10) 102.248(11) 79.193(5) 74.910(2) 90 
Volume[Å3] 7589.4(3) 4434.5(4) 2071.84(4) 2028.2(4) 2064.5(2) 2010.93(7) 5611.4(3) 
Z 8 8 1 2 2 1 4 
Density 
(Mg/m3) 





3.296 8.432 4.575 3.280 2.029 3.161 2.934 
F(000) 3664 3056 1072 912 984 1002 2672 
Crystal 
size(mm3 ) 
0.280 x 0.150 x 0.015 0.320 × 0.110 × 0.080 0.15 ×0.05 × 0.04 0.45 ×0.32 × 0.14 0.380 x 0.170 x 0.070 0.120 × 0.110 × 0.100 0.350 × 0.170 ×0.046 
Theta range for 
data collection 
2.336 to 27.486°. 1.573 to 25.681°. 2.108 to 27.483°. 1.926 to 29.777°. 2.065 to 25.027°. 2.427 to 27.484°. 1.893 to 29.294°. 
Reflections 
collected 





8310[R(int) = 0.0469] 9493 [R(int) = 0.0417] 10839 [R(int) = 0.0370] 7207 [R(int) =0.0745] 9203 [R(int) = 0.0334] 15019 [R(int) =0.1115] 
Completeness to 
theta = 25.242° 
96.0% 98.7% 99.9% 99.3% 99.1% 99.9% 99.2% 
Data / restraints 
/ parameters 
32137 / 1632 / 2020 8310 / 478 / 487 9493 / 2 / 436 10839/ 465 /424 7207 / 0 / 424 9203 / 20 / 546 15019 / 79 / 638 
Goodness-of-fit 
on F2 
1.118 0.695 1.096 0.946 0.938 1.06 0.855 
Δρmax; Δρmin 
[eÅ–3] 
0.870 and -1.314 1.249 and -0.893 1.566 and -2.250 1.557 and -1.006 2.635 and -1.864 1.530 and -0.548 1.434 and -3.886 
R 1 [I > 2σ(I)] 0.0549 0.0234 0.0363 0.0245 0.0470 0.0190 0.0541 




Cytotoxicity. MTS assay was used to calculate the percentage of viable cells in the culture 
media.  This assay depends on the transformation of a tetrazolium salt into formazan in viable 
cells by mitochondrial dehydrogenase enzyme activity. There is a positive correlation between 
the amount of formazan and the number of viable cells in the culture media. Hela, HCT116, 
HT-29 and HEK 293 cells were seeded in 96 flat bottomed microtiter tissue culture plates with 
20.000 cells per well in 200 μL media McCoy's and Dulbecco's Modified Eagle's Medium 
(DMEM). In order to attach the cells to the well base in the microtiter plates, the plates were 
incubated overnight in a 5% CO2 incubator at 37 °C. After 24 h, the media was removed from 
the wells and 100 μL compound in media was added. Various concentrations of compounds in 
the range from 6.25 mM to 6.25 nM were tested. After 24 h of incubation, the contents of the 
wells were removed using a multipipete and then 180 μL sterilized PBS was added followed 
by the addition of 20 μL MTS reagent (Promega, UK). Plates were then returned to the 
incubator for 4 h. Color intensity (Absorbance) of the treated wells was measured at 490 nm 
using a Synergy HT microplate reader. The percentages of the cell viability of the treated cells 
were calculated based on positive and negative control where they represent 100% and 0% 
viable cells respectively. IC50 values were calculated using GraphPad Prism software.  
RESULT AND DISCUSSION  
Use of 2,2/-diphenylglycine. A convenient entry point into much rhenium(V) oxo chemistry 
is the readily available [ReOCl3(PPh3)2].
38 Reaction of this complex with two equivalents of 
dpgH2 in refluxing ethanol afforded, following work-up, the green complex 
[ReO(dpgH)(dpg)(PPh3)] (1) in moderate to good yield (≤74%). The IR spectrum contained a 
strong band at 955 cm-1 assigned to νRe=O along with strong Re‒P stretches at 1092 cm
-1 and 
νN‒H at 3303 cm
-1. The 31P NMR spectrum displayed a singlet at  5.3 ppm for the PPh3 ligand. 
Single crystals suitable for an X-ray crystal structure determination were grown by diffusing 




structure of 1 is rather complex because there are four chemically-equivalent, but symmetry-
independent molecules in the asymmetric unit. Each of these four molecules features the same 
binding of the ligands but these molecules have phenyl rings in different orientations which 
renders them symmetry-independent. Rather than describe of the four related molecules in 
term, the geometry about the metal for one of these is reported and displayed in Figure 1. (The 
full asymmetric unit and full details of bond lengths about each metal center are in the ESI.) 
The metal ion adopts a distorted octahedral geometry where the main distortion occurs as a 
result of binding through CO− and NH− of the two diphenylglycine-derived ligands. One of 
these (dpgH) is only deprotonated at the acid, but is bound through the NH2 (Re(1)-N(1) 
2.250(5)Å). The second is twice-deprotonated, ie dpg, once at the carboxylic acid and once at 
the amine, and it binds through COO‒ and NH‒. Accordingly, the two Re‒N bond lengths are 







Figure 1. Molecular structure of one metal ion in [ReO(dpgH)(dpg)(PPh3)] (1). Selected bond 
lengths (Å) and angles (o): Re(1)-O(1) 1.705(4), Re(1)-O(5) 2.064(4), Re(1)-O(7) 2.025(3), 
Re(1)-N(1) 2.250(5), Re(1)-N(2) 1.889(5), Re(1)-P(1) 2.4487(13); O(5)-Re(1)-N(1) 73.85(15), 
O(1)-Re(1)-O(7) 104.88(15), N(2)-Re(1)-O(7) 80.47(16), O(5)-Re(1)-P(1) 88.69(10). 
 
 
It proved possible to obtain 1 by use of a similar reaction but employing [ReO2I(PPh3)2] as 





With a view to conducting biological assays, we decided to employ the phosphine 1,2,3-
triaza-7-phosphaadamantane (PTA). Treatment of [ReO(OEt)I2(PPh3)2] with three equivalents 
of  PTA in dichloromethane/ethanol afforded, after work-up, the complex [ReO(OEt)I2(PTA)2] 
(2) in high yield. The IR spectrum was dominated by the signals of νRe=O at 945 cm
-1 and 902 
cm-1 for ν(O‒CH2). Also, the IR spectrum contained strong bands of coordinated PTA ligand at 
969 and 1013 cm-1. The 1H NMR spectrum exhibited methylene protons for PTA between 4.03 
and 4.74 ppm, while there were no signals displayed for the aromatic groups related to a PPh3 
ligand. The 31P NMR spectrum showed a singlet at -4.8 ppm, suggesting the presence of two 
equivalent PTA ligands. 
Single crystals suitable for a structure determination were grown via diffusion of 
dichloromethane /ethanol at ambient temperature. Structure determination for the crystal at 150 
K was routine and this demonstrated that 2 crystallized with two chemically identical molecules 
in the asymmetric unit (Z = 2) in space group P21/n. 
The molecular structure is shown in figure 2, with bond lengths and angles given in the 
caption. Each rhenium center adopts a distorted octahedral geometry with one bulky PTA 





Figure 2. Molecular structure of [ReO(OEt)I2(PTA)2] (2). Selected bond lengths (Å) and 
angles (o): Re(1)-O(1) 1.706(5), Re(1)-O(3) 1.906(5), Re(1)-I(1) 2.8117(5), Re(1)-I(2) 
2.7450(5), Re(1)-P(1) 2.4673(17), Re(1)-P(2) 2.4523(17); O(1)-Re(1)-O(3) 172.6(2), P(2)-
Re(1)-P(1) 176.27(6), O(1)-Re(1)-I(2) 95.59(16), C(31)-O(3)-Re(1) 146.9(4), O(3)-C(31)-
C(32) 111.9(6). Re(2)-O(2) 1.705(5), Re(2)-O(4) 1.906(5), Re(2)-I(3) 2.7519(5), Re(2)-I(4) 
2.8080(5), Re(2)-P(3) 2.4555(17), Re(2)-P(4) 2.4631(17); O(2)-Re(2)-O(4) 174.3(2), P(3)-
Re(2)-P(4) 176.24(6), O(2)-Re(2)-I(3) 94.42(15), C(33)-O(4)-Re(2) 152.0(4), O(4)-C(33)-
C(34) 111.2(5).  
The two independent complexes in the asymmetric unit are related by psuedo translational 
symmetry. Upon warming of the crystal, the structure simplifies and the pseudo translation 
becomes a strict symmetry element. The structure at 298 K crystallises in the space group C2/c 
with a single Re complex in the asymmetric unit (Z = 4) (ESI, figure S3). There is small-scale 
disorder of the position of the ethoxide alkyl chain in this structure, which suggests the presence 




The reaction of [ReOI2(PTA)3] with two equivalents of dpgH2 in ethanol afforded, after 
work-up, the complex [Re(NCPh2)(PTA)3I2]0.5EtOH (3·0.5EtOH). The infrared spectrum of 
3 exhibited the signals of PTA ligands at 946, 969 and 1015 cm-1, together with a weak band 
for νN=C at 1592 cm
-1. Also, in the IR spectrum symmetric νP‒CH2 was found at 1313 cm
-1, whilst 
νN–CH2 and νN–C–N were observed at 1276 and 1241 cm
-1, respectively. The 1H NMR spectrum 
displayed signals for methylene protons of PTA between 3.66 and 4.08 ppm as well as 
aromatics  between 7.05 and 7.29 ppm. The 31P NMR spectrum (C6D6) exhibited (similar shifts 
were noted in CDCl3, see experimental) a triplet and doublet at  -104.9 and -120.9 ppm; these 
shifts (and those of 4 and 5) are somewhat downfield of those reported for the complex 
[ReNCl2(PTA)3] (-78.2 and -74.5 ppm in CDCl3).
24 This data is consistent with the presence 
of two equivalent and one other PTA ligands. In order to assess the stability of complex 3, a 
sample of 3 was dissolved in D2O and monitored by 
31P NMR spectroscopy. The spectrum 
showed the peak of one PTA at -107.3 ppm and two PTA ligands trans to each other at -123.3 
ppm. The two signals look similar to the triplet-doublet pattern of 3 in C6D6 (-104.9 and -120.9 
ppm). Complex 3 was isolated as single crystals from EtOH and the crystal structure 
determined by X-ray diffraction. The molecular structure is shown in figure 3 (for an alternative 
view see figure S4, ESI), with selected bond lengths and angles given in the caption. The 
rhenium center adopts a distorted octahedral geometry in which the phosphine Re(1)–P(1) 
binds trans to the Re(1)–P(3). The distortion occurs as a result of the bulky nature of all the 
ligands present.  
In accordance with the structure of 3, the Re(1)–P(1) and Re(1)–P(3) bonds found in the 
trans positions each display longer distances of 2.3929(12) and 2.4004(12) Å. The Re1-I2 bond 
lengthening of 2.8652(4) Å can be ascribed to trans influence exerted by the Re(1)‒N(10) that 




complexation in previous studies,39,40 whilst a search of the CSD for MNCPh2 or MNCHPh2 
type motifs revealed 19 hits.
39,41,42 
A similar reaction but using [ReOCl2(PTA)3] and [ReOBr2(PTA)3] also resulted after work-
up in the isolation of a green complex of formula [Re(NCPh2)(PTA)3Cl2]·2EtOH  (4·2EtOH) 
and [Re(NCPh2)(PTA)3Br2]·1.6EtOH (5·1.6EtOH) respectively. However, a single crystal X-
ray diffraction study revealed that although the geometry at the metal is essentially the same as 
in 3, there are different amounts of solvent present. The molecular structures for complexes 
4·2EtOH and 5·1.6EtOH are shown in figure 4 (for alternative views see figures S5 and S6, 
ESI), with selected bond lengths and angles given in the caption. 
 
Figure 3. Molecular structure of 3·0.5EtOH (unbound ethanol not shown). Selected bond 




Re(1)-P(2) 2.3911(11), Re(1)-P(3) 2.4004(12) N(10)-Re(1) 1.817(4), N(10)-C(19) 1.279(6); 
I(1)-Re(1)-I(2) 82.391(11), P(2)-Re(1)-P(1) 94.14(4), Re(1)-N(10)-C(19) 179.3(3).    
 
Figure 4. Molecular structures of 4·2EtOH and 5·1.6EtOH. Selected bond lengths (Å) and 
angles (o): For 4·2EtOH: Re(1)-Cl(1) 2.4517(7), Re(1)-Cl(2) 2.4608(8), Re(1)-P(1) 2.4095(8), 
Re(1)-P(2) 2.4009(7), Re(1)-P(3) 2.4310(8), Re(1)-N(10) 1.804(2), N(10)-C19) 1.300(3); 
Cl(1)-Re(1)-Cl(2) 85.79(3), P(2)-Re(1)-P(1) 92.46(3), Re(1)-N(10)-C(19) 177.5(2). For 5: 
Re(1)-Br(1) 2.5960(9), Re(1)-Br(2) 2.6499(9), Re(1)-P(1) 2.3875(19), Re(1)-P(2) 2.387(2), 
Re(1)-P(3) 2.3923(19), Re(1)-N(10) 1.801(6), N(10)-C19) 1.307(9); Br(1)-Re(1)-Br(2) 
82.88(3), P(2)-Re(1)-P(1) 95.69(7), Re(1)-N(10)-C(19) 177.4(5).     
 
Use of benzilic acid. The reaction of [ReO(OEt)I2(PTA)2] (2) with two equivalents of 
benzilic acid in ethanol afforded, after work-up, the complex 
[ReO(benz)2(PTA)][PTAH]·EtOH (6·EtOH). The infrared spectrum of 6 exhibited bands for 
the PTA ligand at 1025 cm-1, together with νRe=O stretching at 945 cm
-1. The 1H NMR spectrum 
displayed signals for the methylene protons of PTA between 2.91 and 3.29 ppm as well as 




two PTA ligands at -90.4 and -94.5 ppm. The stability of 6 was examined in D2O via 
31P NMR 
spectroscopy, which revealed two singlets at -88.5 and -91.6 ppm, similar to the signals 
observed for complex 6 in C6D6 albeit with slightly downfield shifts. The complex is 
completely soluble in benzene and less soluble in water. For example in 5 mL D2O, when 100 
mg of 6 was dissolved, after filtration, the remaining undissolved solid weighed 40 mg, i.e. 60 
wt% uptake.  
Complex 6 was isolated as single crystals from EtOH and examined by X-ray diffraction. 
The molecular structure is shown in figure 5 (for an alternative view see figure S7, ESI), with 
selected bond lengths and angles given in the caption. The rhenium center adopts a distorted 
octahedral geometry in which the phosphine (Re(1)–P(1) = 2.3904 Å) binds trans to the oxygen 
of an acid group. The main distortion occurs as a result of the chelate binding of the two 
deprotonated benzilic acid derived ligands. A protonated PTA forms a hydrogen bond with one 
of the CO benzilic groups. The Re=O bond distance at 1.7009(15) Å is typical.41 The Re1-O1 
bond lengthening of 2.1238(14) Å can be ascribed to the trans influence exerted by the Re1-





Figure 5. Molecular structure of 6·EtOH. The dashed line indicates a hydrogen bond. Selected 
bond lengths (Å) and angles (o): Re(1)-O(1) 2.0697(14), Re(1)-O(3) 1.9624(14), Re(1)-O(4) 
2.1238(14), Re(1)-O(6) 1.9677(14), Re(1)- O(7) 1.7009(15), Re(1)-P(1) 2.3904(5); O(7)-
Re(1)-O(1) 97.28(6), O(3)-Re(1)-O(1) 81.02(6), O(6)-Re(1)-O(4) 75.49(6), O(7)-Re(1)-P(1) 
89.32(5). 
 
Potential to form a technetium-99m analogue compound. In order that the systems herein 
could be investigated and developed as radiopharmaceuticals, it is necessary (given the 6 h 
half-life of 99mTc, used for SPECT imaging) that the product preparation can be conducted from 
perrhenate in about 4 h. We have chosen perrhenate as the starting material, given the usual 
source of 99mTc generated from clinical grade generators in hospital radiopharmacies is 
pertechnetate.5 With this in mind, the product [Re(NCPh)(dpg)I(PTA)3] (7) was obtained in 4 
h by preparing [ReO2I(PPh3)2] (from (NH4)[ReO4]) then exchanging the PPh3 ligands with PTA 
to afford ReO2I(PTA)3, and then the ReO2I(PTA)3 was reacted with two equivalents of dpgH2 
in ethanol to afford, after work-up, a mixture comprising 85% of  complex 7 and 15% of 





Scheme 3. ‘One-pot’ 4 h preparation of 3 and 7 from perrhenate. 
 
The IR spectrum of 7 exhibited signals associated with PTA ligands in the range of 1012 and 
1035 cm-1, together with νRe‒O stretching at 945 cm
-1 and νNH2 at 3409 cm
-1. The 1H NMR 
spectrum displayed signals for the methylene protons of PTA between 3.55 and 4.34 ppm as 
well as aromatics between 6.82 and 7.64 ppm. Complex 7 was isolated as single crystals from 
benzene-d6 and was examined by X-ray diffraction. The molecular structure is shown in figure 
6 (for an alternative view see figure S8, ESI), with selected bond lengths and angles given in 
the caption. The rhenium center adopts a distorted octahedral geometry in which the phosphine 
Re(1)–P(1) binds trans to the Re(1)–P(3). One of the dpg ligands has lost CO2 and binds to the 
rhenium via the nitrogen atom, in a similar fashion to that observed in 3. The second 
diphenylglycine-derived ligand is deprotonated at the carboxylic acid and it binds in a 
monodentate fashion through a single oxygen atom of the carboxylate. Similar to the structure 
3, the Re(1)–P(1) and Re(1)–P(3) bond in a trans fashion, and display long distances at 
2.3932(18) and 2.4017(18) Å, respectively. The Re(1)–I(1) bond lengthening of 2.8101(5) Å 
can be ascribed to the trans influence exerted by Re(1)–P(2) that itself has a bond length 
2.3980(16) Å. The Re(1)–O(1) bond lengthening of 2.158(5) Å can also be ascribed to the trans 
influence exerted by Re(1)–N(10) which has a bond length of 1.801(5) Å. 
The geometrical parameters associated with the MNCPh2 motif for 3, 4, 5 and 7 are compared 
in fig. S9, ESI. This motif has been called azavinylidene or alkyleneamide,41 and it is clear 
there is double bond character associated with the R – N bond. Given the linearity observed 
here for the Re – N – C angles (> 177 o), we favor the description put forward by Pombeiro et 





This then, in terms of electron counting, gives an 18 electron count for the complexes 3, 4, 5 
and 7. 
 
Figure 6. Molecular structure of 7·2C6D6. Benzene molecules within the crystal structure are 
not shown. Selected bond lengths (Å) and angles (o): Re(1)-O(1) 2.158(5), Re(1)-N(10) 
1.801(5) Re(1)-P(1) 2.3932(18), Re(1)-P(2) 2.3980(16), Re(1)-P(3) 2.4017(18), Re(1)-I(1) 
2.8101(5), N(10)-C19) 1.305(8): Re(1)-N(10)-C(19) 177.8(5), N(10)-Re(1)-O(1) 173.3(2), 
N(10)-Re(1)-P(1) 89.17(16), O(1)-Re(1)-P(1) 84.32(15), N(10)-Re(1)-P(2) 96.65(16). 
Cell viability studies. The complexes 3, 4, 5, 6 and 7 were tested for cytotoxicity against 
cancerous cell lines (Hela, HCT116 and HT-29) to show that they are non-toxic at 
concentrations used for imaging. The IC50 values were determined using the cell viability assay, 
MTS. All compounds in this study are non-toxic in the concentration range used in SPECT 
medical imaging (nM-pM) with IC50 values in the range 29.87–1858 μM. MTS graphs for 




shown in the Supporting Information figures S10 – S31. Table 2 summarises the IC50 values 
of the complexes synthesized. 
The analogues compounds 3, 4, and 5 show enhanced toxicity in Hela cells in comparison to 
that of compounds 6 and 7, although in colon cancer cell lines (HCT116 and HT-29) 
compounds 6 and 7 show the higher toxicity (Table 2). When studying compounds 3, 6 and 7 
in a non-cancerous cell line there is a dramatic decrease in toxicity in to the high µM and mM 
range, suggesting a preference for anti-tumor toxicity. The most potent compounds in colon 
cancer cell lines (3, 6, and 7) appear to be derived from the iodo starting materials. Looking 
close at the change of halogen with respect to IC50 values the trend followed is I>Br>Cl, which 
correlates to size of halogen and more labile atom under aqueous environment. The bond 
distance between the Re metal and the halogen increases with toxicity from 2.86 Å (Re-I), 2.64 
Å (Re-Br) and 2.46 Å (Re-Cl), suggesting that the mechanism of action is direct binding of a 
protein or DNA to the metal centre, in a similar manner to that of cisplatin. The IC50 values 
observed here are slightly higher than that of cisplatin for the cancer cell lines (Table 2).44,45 
The addition of the two benzilic acid or diphenylglycine ligands in 6 and 7 with regards to 
HeLa cells must allow for access to mechanism of resistance in this cell line. Although the 
mechanism of action has not been explored, it is clear that the change in structure either amino 
acid ligands or halogen has an effect on the IC50 value. To check the biostability of compound 
3 and 7, a 10 µl of compound (6.25 mM) was diluted in 100 µl of biological media (DEME) 
and monitored by 31P NMR spectroscopy over a period of 5 days; the spectral form does not 
change across the study (Figures S31 – S35). This suggests that the coordination of the water-
soluble phosphine ligand (PTA) remains on the metal centre and these are not removed as part 
of the mechanism of action within the cells.  This also suggest that the complexes have a good 
















(3) 47.17 ± 1.207 40.69 ± 2.584 49.57 ± 5.833 574.7 ± 0.836 
(4) 86.62 ± 1.032 84.47 ± 1.876 88.22 ± 2.491 - 
(5) 71.72 ± 1.415 37.12 ± 2.358 72.04 ± 1.745 - 
(6) 123.60 ± 0.6227 29.87 ± 2.312 37.29 ± 1.699 662.1 ± 1.062 
(7) 140.10 ± 1.045 42.92 ± 2.117 34.38 ± 3.073 1858 ± 1.377 
Cisplatin 5.45 ± 0.44 42 8.2 ± 0.14 43 2.7 ± 0.86 43 109 ± 12 44 
 
 
Synthesis of novel technetium-99m phosphadamantane precursor. An attempt was made 
to translate these protocols to produce technetium-99m analogues of the rhenium complexes. 
Multistep protocols, such as this, are challenging to translate to radiochemistry where the 
amounts of the metal ion isotope precursor are limited and the concentrations are low (due to 
accessible amounts of the radioisotope and radiation protection issues), After several attempts 
and development of an optimised protocol to produce [99mTc][TcO2I(PPh3)2] and, 
subsequently, [99mTc][TcOI2(PTA)3] from the commercial radioisotope generator supplying 
[99mTc]pertechnetate, the reaction with diphenylglycine was attempted. Despite the use of 
various different conditions (including varying temperature, dpgH2 concentration and time of 
reaction), the target compound [99mTc][Tc(NCPh2)I2(PTA)3] could not be accessed. Further 
method development is required to produce the technetium analogues from these precursors in 









In conclusion, we have used the precursors [ReOCl3(PPh3)2] and [ReO2I(PPh3)2] to access a 
number of new water soluble phosphine complexes of rhenium via reaction with 1,2,3-triaza-
7-phosphaadamantane (PTA) and the acids diphenylglycine or benzilic acid. Seven complexes 
have been successfully synthesized and fully characterized, and in a number of cases (eg 3 and 
7), the acid derived ligand has lost CO2 during complexation. 
Complexes 3, 4, 5, 6 and 7 have been screened for their anti-proliferative activity against various 
cancer cell lines in order to show a non-toxic behavior at injected doses for SPECT medical imaging.  
Preliminary studies to form a technetium-99m analogue show that the [99mTc][TcOI2(PTA)3] 
complex was successfully synthesized, however the final dpgH2 complex with 
99mTc remains 
elusive, under the reaction conditions attempted in this study. Further development of routes to the 
[99mTc][TcdpgH2] complexes is required to allow future potential applications in SPECT imaging 
to be explored. It is a significant advance to have synthesized these novel compounds with the 
rhenium analogues in a procedure that can be carried out on an appropriate timescale for transfer to 
radiopharmaceutical production.   
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